🔎 Trials Near Me

Home › Leukemia › Massachusetts › Boston

Leukemia clinical trials in Boston, MA

25 studies for Leukemia are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

RecruitingPhase 2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04996875

Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

Recruiting
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06907797

CIML NK Cells With Venetoclax for AML

RecruitingPhase 1
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT06152809

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

RecruitingPhase 1
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 18 to 90 · All sexes · Updated Aug 26, 2026 · NCT07439211

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RecruitingPhase 1
  • Beth Israel Deaconess Medical Center, Boston
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788

ALL Backbone in AYAs

RecruitingPhase 2
  • Dana Farber Cancer Institute, Boston
Ages 18 to 51 · All sexes · Updated Aug 17, 2026 · NCT07227584

Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention

Recruiting
  • Mass General Brigham Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Jul 27, 2026 · NCT07671209

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

RecruitingHealthy volunteers welcome
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06469307

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

RecruitingPhase 1
  • Dana-Farber Cancer Institute, Boston
  • Brigham and Women's Hospital, Boston
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT06138587

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

RecruitingPhase 1
  • Boston Children's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ages 12 and older · All sexes · Updated Jun 17, 2026 · NCT04024761

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

RecruitingPhase 1/2
  • Dren Investigational Site, Boston
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT05475925

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

RecruitingPhase 1
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated May 28, 2026 · NCT03219450

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

RecruitingObservational study
  • Dana-Farber Cancer Institute, Boston
All ages · All sexes · Updated May 18, 2026 · NCT01790152

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

RecruitingPhase 2/3
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Recruiting
  • Massachusetts General Hospital Cancer Center, Boston
Ages 18 and older · All sexes · Updated Apr 21, 2026 · NCT05646576

Shwachman Diamond Syndrome Registry and Study

RecruitingObservational study
  • Boston Children's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
All ages · All sexes · Updated Apr 6, 2026 · NCT06056908

Revumenib in Combination With 7+3 + Midostaurin in AML

RecruitingPhase 1
  • Dana-Farber Cancer Institute, Boston
Ages 18 to 75 · All sexes · Updated Mar 25, 2026 · NCT06313437

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RecruitingPhase 1
  • Massachusetts General Hospital, Boston
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

RecruitingPhase 1/2
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Feb 11, 2026 · NCT06644183

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

RecruitingPhase 1/2
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Feb 5, 2026 · NCT07148180

Mosunetuzumab for CLL MRD Clearance

RecruitingPhase 1/2
  • Brigham & Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT07052695

I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients

Recruiting
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
  • Massachusetts General Hospital Cancer Center, Boston
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT05842603

HEME Home Transfusion Program

Recruiting
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 18 and older · All sexes · Updated Sep 17, 2025 · NCT06487247

About Leukemia

Leukemia is cancer of the white blood cells. There are two types of Leukemias, acute and chronic. Learn about the differences and treatments available.

More about Leukemia on MedlinePlus

Leukemia trials in other cities

Other studies in Boston

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.